Article info
PDFBasic and translational research
Extended report
Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis
- Correspondence to Dr Jörg H W Distler, Department of Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Ulmenweg 18, D91054 Erlangen, Germany; joerg.distler{at}uk-erlangen.de
Citation
Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis
Publication history
- Received November 14, 2016
- Revised May 29, 2017
- Accepted July 18, 2017
- First published August 16, 2017.
Online issue publication
January 09, 2022
Article Versions
- Previous version (1 November 2019).
- Previous version (1 November 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.